-
Views
-
Cite
Cite
Renyuan Bai, I-Mei Siu, Betty M. Tyler, Verena Staedtke, Gary L. Gallia, Gregory J. Riggins, Evaluation of retinoic acid therapy for OTX2-positive medulloblastomas, Neuro-Oncology, Volume 12, Issue 7, July 2010, Pages 655–663, https://doi.org/10.1093/neuonc/nop062
- Share Icon Share
Abstract
The homeobox transcription factor OTX2 plays an essential role during embryonic brain development. It is normally silenced in the adult brain, but is overexpressed by genomic amplification or other mechanisms in the majority of medulloblastomas (MBs). Retinoic acids (RAs) can suppress OTX2 expression and inhibit MB growth. In this study, 9-cis RA most potently inhibited MB cell growth. 9-cis RA functions through the downregulation of OTX2 expression, which subsequently induces neuronal differentiation of OTX2-expressing cells. Treatment with 9-cis RA reduced the growth of D425 flank xenograft tumors in mice. In an intracranial model, however, MB tumors showed resistance to 9-cis RA treatment, and we implicated fibroblast growth factor (FGF) as a potential mediator of resistance to RA therapy. These findings suggest a mechanism for RA-mediated anti-tumor effect on OTX2-positive MB cells and indicate that therapeutic targeting of OTX2 might be effective if FGF pathway-mediated resistance can be overcome.
- renal artery stenosis
- fibroblast growth factors
- renin-angiotensin-aldosterone system
- rotational atherectomy
- cell growth
- adult
- cell lines
- down-regulation
- embryo
- genome
- medulloblastoma
- retinoids
- transplantation, heterologous
- tretinoin
- brain
- mice
- neoplasms
- transcription factor
- reticular activating system
- brain development
- amplification
- neuron differentiation
- modified barium swallow
- recurrent aphthous ulcer